Shares of biopharmaceutical company Soleno Therapeutics, Inc. (SLNO) were in the spotlight on Monday after the company ...

Soleno Therapeutics (SLNO) announced the U.S. commercial availability of VYKAT XR extended-release tablets, the company’s treatment for ...

Amendment reflects improved covenants and aligns with Company's strategic focus on cannabis VANCOUVER, British Columbia, April 14, 2025 (GLOBE NEWSWIRE) -- Village Farms International, Inc. ("Village ...

First prescriptions delivered to individuals with PWSREDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno ...

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).

Vykat XR was recently approved in the U.S. and helps control the constant hunger that dominates the lives of those with the condition. Harvey Price, the son of celebrity Katie Price, is among ...

The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome.